Replies to post #1016 on TG Therapeutics Inc (TGTX)

[Android 2-73]

that makes sense logically.

[postmeridiem]

During the presentation, TGTX compared TG-1101 to ocrelizumab (Ocrevus), which is currently in use for b-cell depletion in MS. TGTX did not claim a safety advantage or an efficacy advantage over ocrelizumab. They said their advantages will be convenience and cost if the drug is approved.

Adverse events in CAR-T cancer trials are not relevant to the MS trial.